121 eyes were treated with steroid monotherapy three times a day (t.i.d.) for three weeks, 163 eyes were treated with NSAID monotherapy t.i.d. for three weeks, and 164 eyes were treated with steroid and NSAID combination therapy t.i.d. for three weeks. The length of the anti-inflammatory treatment reflected the real-life clinical practice.
20
Steroid treatment included dexamethasone (N = 103, Monopex, 1 mg/ml, Laboratoires Théa, Clermont-Ferrand, France; or Oftan Dexa, 1 mg/ml, Santen Pharmaceutical Co. Ltd, Osaka, Japan) or prednisolone acetate (N = 18, Pred Forte, 10 mg/ml, Allergan Inc. Irvine, CA). NSAID treatment was carried out with diclofenac (N = 104, Voltaren Ophtha, 1 mg/ml, Laboratoires Théa; or Dicloabak, 1 mg/ml, Laboratoires Théa) or nepafenac (N = 59, Nevanac, 1 mg/ml, Novartis, Basel, Switzerland). Of the eyes treated with combination therapy, 118 (72%) were administered prednisolone acetate and nepafenac and 46 (28%) dexamethasone and diclofenac.